COVID-19 updates, including vaccine information, for our patients and visitors Learn More

Menu
Search

UCSD Begins Sudden Deafness Study

 

September 22, 2005  |  

UCSD Department of Otolaryngology, in conjunction with eight other medical centers around the country, is conducting research on treatments for sudden deafness, known clinically as sudden sensorineural hearing loss (SSNHL). SSNHL is new onset hearing loss in one ear that develops within a 72-hour period or less.

The condition affects between five and 20 per 100,000 individuals every year, and about 52,000 new cases are diagnosed annually in the United States. Though physicians theorize the condition might be caused by a virus infection, there is no obvious cause for the majority of cases of SSNHL.

Symptoms of SSNHL include hearing loss, tinnitus (ringing in the ears), and possibly dizziness or vertigo. A feeling of ear fullness is also a common symptom of the condition. The fact that ear fullness is a common sensation can cause people to delay seeking medical attention. However, SSNHL is potentially reversible and immediate recognition is critical, as delay in treatment may result in permanent hearing loss.

Presently, there are two treatments for SSNHL: administration of oral steroids and injection of steroids directly into the ear, known as intratympanic (IT) therapy. Though both treatments have benefited patients in varying degrees, only 13 randomized controlled studies have been conducted on treatments for SSNHL and only oral steroid treatment has been shown to have a definite benefit. No well-designed studies have been done to prove the benefit of IT steroids.

The current study, a randomized controlled clinical trial sponsored by the National Institute of Health (NIH) Institute of Deafness and Other Communication Disorders (NIH–NIDCD), seeks to examine the effectiveness of IT steroid treatment for SSNHL, and compare its benefits and risks to conventional oral steroid therapy.

Moreover, publication of the study will create raised awareness of SSNHL, resulting in the possibility of earlier evaluation and diagnosis, and higher treatment success rates.

For more information call Sherrie Glassmeyer at 858-657-6836.

# # #

News Media Contact Jeffrey Itrich 619-543-6163

UCSD Health Sciences Communications HealthBeat: /news/




Media Contact

Share This Article


Related News

4/14/2021
The UC San Diego Autism Center for Excellence has received a $1.5 million gift from Kristin Farmer, founder and chief executive officer of ACES, a company that provides services to children with autis ...
4/2/2021
UC San Diego researchers found that the chemical inhibitor K777 reduces the coronavirus’ ability to infect cell lines by blocking human enzyme cathepsin L; clinical trials are underway.
4/1/2021
UC San Diego students will participate in nationwide clinical trial to assess if COVID-19 vaccination prevents infection and reduces risk of transmission.
4/1/2021
$1.1 million gift from philanthropist Ann Bedell Hunt establishes Bedell Family Endowed Medical Scholarship at UC San Diego School of Medicine in memory of her father, Omar Jaspering, and in honor of ...



Follow Us